Prediabetes represents an intermediate state of hyperglycemia that predisposes individuals to the development of type 2 diabetes and other cardiovascular complications. Landmark trials such as the Da Qing study, the Finnish Diabetes Prevention Study and the Diabetes Prevention Program have shown that intensive lifestyle modification can reduce the risk of diabetes development. However, there are challenges in delivering lifestyle modification on a large scale. Metformin or acarbose may be as effective as the lifestyle interventions in certain high-risk subgroups, such as the obese or those with a history gestational diabetes mellitus. Use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-ra) in nondiabetic and prediabetic populations also reduced the risk of type 2 diabetes. The purpose of this Research Topic is to highlight the roles of traditional and newer pharmacotherapy agents in diabetes prevention, either alone or in adjunct to lifestyle modification.
This Research Topic aims to present the latest evidence about the role of pharmacological interventions in the prevention of type 2 diabetes. These include efficacy, safety, and long-term effectiveness of established therapies such as metformin and newer therapeutic agents. We welcome articles highlighting the latest data on safety, efficacy, and long-term effectiveness of different pharmacotherapies in diabetes prevention. We also welcome articles addressing precision prevention in those with prediabetes and the identification of clinical, genetic, dietary, microbial, or other biomarkers that may predict response to pharmacological interventions.
We welcome Original Research articles, Reviews, Systematic Review, Clinical Trials on the following sub-topics, including but not limited to:
• Use of metformin or acarbose in prediabetes
• Use of newer glucose lowering agents such as sodium glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists in diabetes prevention
• Evidence for novel therapies, including traditional Chinese Medicines in diabetes prevention
• Identifying populations who would benefit from pharmacological therapies
• Long-term effectiveness and safety of pharmacological interventions versus lifestyle modification in diabetes prevention and comparative analyses
• Precision prevention in prediabetes
Prediabetes represents an intermediate state of hyperglycemia that predisposes individuals to the development of type 2 diabetes and other cardiovascular complications. Landmark trials such as the Da Qing study, the Finnish Diabetes Prevention Study and the Diabetes Prevention Program have shown that intensive lifestyle modification can reduce the risk of diabetes development. However, there are challenges in delivering lifestyle modification on a large scale. Metformin or acarbose may be as effective as the lifestyle interventions in certain high-risk subgroups, such as the obese or those with a history gestational diabetes mellitus. Use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-ra) in nondiabetic and prediabetic populations also reduced the risk of type 2 diabetes. The purpose of this Research Topic is to highlight the roles of traditional and newer pharmacotherapy agents in diabetes prevention, either alone or in adjunct to lifestyle modification.
This Research Topic aims to present the latest evidence about the role of pharmacological interventions in the prevention of type 2 diabetes. These include efficacy, safety, and long-term effectiveness of established therapies such as metformin and newer therapeutic agents. We welcome articles highlighting the latest data on safety, efficacy, and long-term effectiveness of different pharmacotherapies in diabetes prevention. We also welcome articles addressing precision prevention in those with prediabetes and the identification of clinical, genetic, dietary, microbial, or other biomarkers that may predict response to pharmacological interventions.
We welcome Original Research articles, Reviews, Systematic Review, Clinical Trials on the following sub-topics, including but not limited to:
• Use of metformin or acarbose in prediabetes
• Use of newer glucose lowering agents such as sodium glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists in diabetes prevention
• Evidence for novel therapies, including traditional Chinese Medicines in diabetes prevention
• Identifying populations who would benefit from pharmacological therapies
• Long-term effectiveness and safety of pharmacological interventions versus lifestyle modification in diabetes prevention and comparative analyses
• Precision prevention in prediabetes